Literature DB >> 19007321

Current and emerging paradigms in the therapeutic management of atherosclerosis.

Atul Tiwari1.   

Abstract

BACKGROUND: The pathogenesis of atherosclerosis lies in abnormalities in lipoprotein metabolism leading to pathological interactions with vessel walls and the release of inflammatory components, which further aggravate the disease condition.
OBJECTIVE: To elucidate current and emerging trends in drug discovery towards the development of new entities regulating lipoprotein metabolism and inflammatory components to combat the progression of atherosclerosis.
METHODS: Research/review articles in the public domain and press releases were employed. RESULTS/
CONCLUSION: With the recent failure of torcetrapib and succinobucol, drug discovery and development efforts towards the treatment of atherosclerosis have received a big jolt and have been slowed down to a certain extent [corrected]. But this could be a starting point for several new mechanisms that are emerging to discover new drugs to combat the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007321     DOI: 10.1517/14728220802544061

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  1 in total

1.  Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.

Authors:  Ondřej Jurček; Satu Ikonen; Lucie Buřičová; Martina Wimmerová; Zdeněk Wimmer; Pavel Drašar; Jan Horníček; Adéla Galandáková; Jitka Ulrichová; Erkki T Kolehmainen
Journal:  Molecules       Date:  2011-11-10       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.